Continuing Pneumococcal Vaccination After Gavi Transition in Kenya at Full Price is Cost-effective and Could Save Thousands of Lives

This news release was originally published on EurekAlert. Below is an excerpt from the news release.

Co-led by the London School of Hygiene & Tropical Medicine and the KEMRI-Wellcome Trust Research Program, the Pneumococcal Conjugate Vaccine Impact Study estimated that continuing the vaccine beyond 2022 would prevent – in the first ten years – more than 100,000 children and adults from contracting pneumococcal disease and save the lives of 14,000 children and adults who would otherwise have died.

The cost per year of healthy life saved (US $153) was considerably less than Kenya’s annual gross domestic product (GDP) per person (US $1,790 in 2018), which meets – and far exceeds – the World Health Organization (WHO) GDP-related threshold for ‘very cost-effective’ health interventions.

The researchers say this study offers important evidence for policymakers at what is a crucial time for countries that have to decide whether to continue vaccine programs that have benefited from Gavi’s subsidy of the cost of vaccines once their economies grow and Gavi support diminishes.

Leave a Reply

Your email address will not be published.

You May Also Like

COVAX Application Materials for AMC Eligible Economies Now Available

The COVAX Facility released the application and guidance documents (“application package”) for eligible economies to (i) confirm participation in the COVAX Facility and (ii) request support as part of COVAX. This comprises COVID-19 vaccines, as well as Cold Chain Equipment and Technical Assistance needed to prepare for the delivery of COVID-19 vaccines.  All 92 AMC Eligible … Continued

New Evidence Shows Investments in Vaccination Produce Even Greater Returns than Previously Thought

This article originally appeared on Gavi’s website.  The Decade of Vaccine Economics (DoVE) Project, carried out by the Johns Hopkins Bloomberg School of Public Health’s International Vaccine Access Center (IVAC) for nearly ten years, has computed the return-on-investment for vaccines preventing ten infectious diseases in 94 low- and middle-income countries, including 73 countries that have received support from … Continued

COVID-19: Gavi steps up response to pandemic

Gavi, the Vaccine Alliance, will provide US$ 29 million in urgent initial funding to 13 lower-income countries to support their response to COVID-19, helping them to protect health care workers with personal protective equipment (PPE), perform vital surveillance and training, and fund diagnostic tests. There are further requests or interest from 21 countries, meaning more … Continued